Chinese biotech firm Rec-Biotechnology (RecBio) has secured over 1.5 billion yuan ($227.4 million) in its Series B round to fund the clinical trials of its product candidates including recombinant COVID vaccines.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
